Fri, May 31, 7:59 PM (143 days ago)
BioNexus Gene Lab Corp. filed Amendment No. 1 to its Form 10-Q for the quarter ended March 31, 2023, to address a comment from the SEC. This amendment specifically revises Part 1, Item 4 concerning Controls and Procedures. The original filing incorrectly stated that the company's disclosure controls and procedures were "capable," which does not comply with Item 307 of Regulation S-K. The amendment clarifies that the disclosure controls and procedures were not effective as of March 31, 2023. There were no changes to the financial statements or other sections of the original filing. The company's internal controls over financial reporting remained unchanged during the period. This amendment should be read in conjunction with the original filing and other SEC filings by the company.